<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960828</url>
  </required_header>
  <id_info>
    <org_study_id>B-1508/312-004</org_study_id>
    <nct_id>NCT02960828</nct_id>
  </id_info>
  <brief_title>&quot;Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally&quot; Study</brief_title>
  <acronym>SAVE</acronym>
  <official_title>Focal Subthreshold Laser Treatment for Macular Drusen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to validate the efficacy and safety of subthreshold laser photocoagulation on
      high-risk macular drusen in early age-related macular degeneration which has a high risk of
      conversion to exudative AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAVE Study (Stop Early Age-related Macular Degeneration form Vision Loss Eternally)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in drusen size</measure>
    <time_frame>3 month interval</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>3 months interval</time_frame>
    <description>ETDRS and Snellen visual acuity measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drusen distribution</measure>
    <time_frame>3 month interval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in autofluorescence</measure>
    <time_frame>3 month interval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Choroidal Neovascularization</measure>
    <time_frame>3 months interval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>3 months interval</time_frame>
    <description>Contrast Sensitivity Test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Retinal Drusen</condition>
  <arm_group>
    <arm_group_label>Intervention-&quot;Device:_Laser&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subthreshold focal photocoagulation
Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Contralateral eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subthreshold Laser Photocoagulation</intervention_name>
    <description>Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen</description>
    <arm_group_label>Intervention-&quot;Device:_Laser&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal Anti-VEGF injection</intervention_name>
    <description>To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.</description>
    <arm_group_label>Intervention-&quot;Device:_Laser&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subthreshold Laser</intervention_name>
    <arm_group_label>Intervention-&quot;Device:_Laser&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Drusen in both eyes examined under fundoscopy

          -  At least one of the eyes must have high-risk soft drusen

          -  BCVA below ETDRS 83 letters

          -  Patient with consent to participate

        Exclusion Criteria:

          -  Prior diagnosis with choroidal neovascularization

          -  Exudative AMD in at least one eye

          -  If the patient has only one visually effective eye (last eye)

          -  Other macula or retinal diseases than age-related macular degeneration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu Hyung Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyu Hyung Park, M.D., Ph.D.</last_name>
    <phone>82-31-787-7373</phone>
    <email>jiani4@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Na-Kyung Ryoo, M.D.</last_name>
    <phone>82-10-9001-2204</phone>
    <email>nkryoomd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyunggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu Hyung Park, M.D., Ph.D.</last_name>
      <phone>82-32-787-7373</phone>
      <email>jiani4@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Na-Kyung Ryoo, M.D.</last_name>
      <phone>82-10-9001-2204</phone>
      <email>nkryoomd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kyu Hyung Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Na-Kyung Ryoo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Kyu Hyung Park</investigator_full_name>
    <investigator_title>Professor, Chief of department of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Drusen</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

